Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Alexander M.M. Eggermont(University Medical Center Utrecht), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Célèste Lebbé(Inserm), Omid Hamid(Cedars-Sinai Medical Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Cyril Konto(World Trade Organization), Virginia Ferraresi(Cancer Institute (WIA)), Jeffrey S. Weber(NYU Langone Health), Ravichandra Karra Gurunath(European Organisation for Research and Treatment of Cancer), Jedd D. Wolchok(Cornell University), Veerle de Pril(Inserm), Jean‐Jacques Grob(Aix-Marseille Université), Henrik Schmidt(Aarhus University Hospital), Gaetan de Schaetzen(Institut Jules Bordet), Stefan Suciu(St James's University Hospital), Jon Richards(Oncology Specialists), Axel Hoos(GlaxoSmithKline (United States)), Reinhard Dummer(University Hospital of Zurich), Michael Smylie(Inserm), Caroline Robert(Institut Gustave Roussy), Michele Maio(University of Siena)

The Lancet Oncology

April 5, 2015

Cited by 1,258

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2014|5.3k

|Journal of Clinical Oncology|2009|4.6k

Related Papers